Merck to offer 100 million settlement in NuvaRing lawsuits

Merck to offer $100 million settlement in NuvaRing lawsuits
Merck will pay $100 million to settle thousands of lawsuits over the company's NuvaRing birth control device, according to insiders.

(HealthDay)—Merck will pay $100 million to settle thousands of lawsuits over the company's NuvaRing birth control device, according to insiders.

The will be announced Friday and provide an average payout of more than $58,000 per case, two people familiar with the told Bloomberg News. They did not want to be identified because they hadn't been authorized to talk publicly about the accord.

The deal will resolve several thousand cases in federal and state courts in Missouri and New Jersey. Women accused Merck of selling NuvaRing even though the company knew that the device put them at higher risk for than products from other companies.

A Merck spokeswoman declined to comment on the settlement, Bloomberg reported.

More information: Other Health Highlights: Feb. 7, 2014

add to favorites email to friend print save as pdf

Related Stories

Germany's Merck to buy materials supplier AZ

Dec 05, 2013

Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion).

Belgium's Ablynx in Merck cancer research tie-up: firm

Feb 03, 2014

Belgian biotechnology company Ablynx said on Monday it has signed a cancer research cooperation accord with US pharmaceuticals giant Merck & Co. which could be worth up to 1.7 billion euros ($2.3 billion).

Merck's Vioxx cases drag on

Aug 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

Merck: FDA wants more studies of insomnia drug

Jul 01, 2013

Drugmaker Merck & Co. says federal regulators have ruled that they won't approve high doses of its experimental insomnia medication because of concerns about their safety.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

11 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments